Segment Data (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) Segment	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)
Segment Information
Number of reportable segments | Segment			2
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]			srt:ChiefFinancialOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description			The CODM primarily utilizes segment's net comprehensive profit or loss as the key indicator in assessing the segment's performance and allocating resources.
Right-of-use asset	$ 1,062,000		$ 1,062,000		$ 936,000
External revenue	3,083,000	$ 3,108,000	8,276,000	$ 8,180,000
Cost of revenue	532,000	541,000	1,574,000	1,398,000
Research and development	3,658,000	4,043,000	10,653,000	12,008,000
Sales and marketing	1,997,000	2,010,000	6,957,000	4,977,000
General and administrative	4,134,000	3,776,000	13,758,000	12,471,000
Interest	6,000	(162,000)	(65,000)	341,000
Consolidated net comprehensive loss	(9,782,000)	(10,185,000)	(31,222,000)	(29,057,000)
Segment net loss	(9,648,000)	(10,021,000)	(30,804,000)	(29,017,000)
Segment assets	49,472,000		49,472,000		53,425,000
Napo Therapeutics Lease Office | Europe
Segment Information
Right-of-use asset	136,000		136,000		230,000
Property, Plant, and Equipment, Right-of-Use Assets, and Intangible Assets | US
Segment Information
Right-of-use asset	18,700,000		18,700,000		19,600,000
Product revenue, net
Segment Information
External revenue	3,041,000	3,066,000	8,148,000	8,095,000
Operating Segments
Segment Information
External revenue	3,083,000	3,108,000	8,276,000	8,180,000
Cost of revenue	532,000	541,000	1,574,000	1,398,000
Research and development	3,662,000	4,045,000	10,657,000	12,011,000
Sales and marketing	1,997,000	2,010,000	6,957,000	4,977,000
General and administrative	4,658,000	4,271,000	15,240,000	13,922,000
Interest	6,000	(131,000)	(65,000)	425,000
Other segment items	2,399,000	3,258,000	6,640,000	6,051,000
Segment expenses	13,254,000	13,994,000	41,003,000	38,784,000
Consolidated net comprehensive loss	(10,171,000)	(10,886,000)	(32,727,000)	(30,604,000)
Segment assets	226,920,000		226,920,000		218,920,000
Operating Segments | Human Health
Segment Information
External revenue	3,005,000	3,014,000	8,006,000	7,954,000
Cost of revenue	523,000	527,000	1,546,000	1,356,000
Research and development	3,036,000	3,599,000	8,750,000	10,000,000
Sales and marketing	1,935,000	1,946,000	6,632,000	4,768,000
General and administrative	1,898,000	2,288,000	5,901,000	6,700,000
Interest	4,000	32,000	5,000	87,000
Other segment items	393,000	117,000	858,000	354,000
Segment expenses	7,789,000	8,509,000	23,692,000	23,265,000
Consolidated net comprehensive loss	(4,784,000)	(5,495,000)	(15,686,000)	(15,311,000)
Segment assets	45,436,000		45,436,000		44,117,000
Operating Segments | Animal Health
Segment Information
External revenue	78,000	94,000	270,000	226,000
Cost of revenue	9,000	14,000	28,000	42,000
Research and development	626,000	446,000	1,907,000	2,011,000
Sales and marketing	62,000	64,000	325,000	209,000
General and administrative	2,760,000	1,983,000	9,339,000	7,222,000
Interest	2,000	(163,000)	(70,000)	338,000
Other segment items	2,006,000	3,141,000	5,782,000	5,697,000
Segment expenses	5,465,000	5,485,000	17,311,000	15,519,000
Consolidated net comprehensive loss	(5,387,000)	(5,391,000)	(17,041,000)	(15,293,000)
Segment assets	181,484,000		181,484,000		174,803,000
Eliminations And Reconciling Items [Member]
Segment Information
Consolidated net comprehensive loss	389,000	$ 701,000	1,505,000	$ 1,547,000
Segment Reconciling Items
Segment Information
Segment assets	(29,231,000)		(29,231,000)		(29,232,000)
Intersegment Eliminations
Segment Information
Segment assets	$ (148,217,000)		$ (148,217,000)		$ (136,263,000)